Hengrui Launches Apatinib With Echoes Of Icotinib Approach
This article was originally published in PharmAsia News
Jiangsu Hengrui is going all out for its apatinib launch, combining a follow-on study and patient assistance with post-marketing research and local reimbursement talks. Will the comprehensive strategy work for the gastric cancer drug like it has for Betta in the lung cancer market?
You may also be interested in...
Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.